Disc Medicine's three largest insider shareholders as of March 23, 2026 are Venture Fund X, L.P. Atlas (TenPercentOwner, 1.60Mn shares), Holdings A/S Novo (TenPercentOwner, 1.09Mn shares), Braden Michael Leonard (TenPercentOwner, 500.00K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Braden Michael Leonard | 0 | 500,000 | 13 Apr, 2022 | |
| Venture Fund X, L.P. Atlas | 1,402,186 | 198,326 | 25 Jan, 2024 | |
| Holdings A/S Novo | 1,090,772 | 0 | 28 Jun, 2023 | |
| Braden Michael Leonard | 24,750 | 0 | 27 Oct, 2022 | |
| John D Quisel | Chief Executive Officer | 226,064 | 0 | 17 Feb, 2026 |
| Advisors Llc Orbimed | 0 | 186,541 | 26 Mar, 2025 | |
| Mona Ashiya | 0 | 186,541 | 26 Mar, 2025 | |
| William Jacob Savage | Chief Medical Officer | 85,211 | 0 | 04 Mar, 2026 |
| Pamela Stephenson | Chief Commercial Officer | 80,998 | 0 | 17 Feb, 2026 |
| Jean M. Franchi | Chief Financial Officer | 70,990 | 0 | 27 Feb, 2026 |
| Jonathan Yen-Wen Yu | Chief Operating Officer | 54,324 | 0 | 17 Feb, 2026 |
| Rahul Khara | Chief Legal Officer | 52,173 | 0 | 17 Feb, 2026 |
| Joanne Bryce | Chief Financial Officer | 23,665 | 0 | 01 Mar, 2024 |
| Brian Piekos | Cfo | 1,762 | 0 | 02 Jun, 2022 |
| Kevin Bitterman | 0 | 14,013 | 18 Dec, 2025 | |
| Jason Patrick Meyenburg | President Ceo | 1,300 | 0 | 18 May, 2021 |
| Brian Richard Macdonald | Chief Innovation Officer | 12,276 | 0 | 30 Jun, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Mar, 2026 | William Jacob Savage | Common Stock | D | 4,392 | $65.52 | 88,197 | D | S |
| 02 Mar, 2026 | William Jacob Savage | Common Stock | D | 2,986 | $66.41 | 85,211 | D | S |
| 25 Feb, 2026 | Jean M. Franchi | Common Stock | D | 353 | $69.06 | 70,990 | D | S |
| 17 Feb, 2026 | Jean M. Franchi | Common Stock | D | 4,075 | $62.86 | 78,424 | D | S |
| 18 Feb, 2026 | Jean M. Franchi | Common Stock | D | 3,397 | $65.01 | 75,027 | D | S |
| 18 Feb, 2026 | Jean M. Franchi | Common Stock | D | 3,684 | $65.89 | 71,343 | D | S |
| 17 Feb, 2026 | John D Quisel | Common Stock | D | 13,264 | $62.86 | 226,064 | D | S |
| 17 Feb, 2026 | Jonathan Yen-Wen Yu | Common Stock | D | 3,231 | $62.86 | 54,324 | D | S |
| 17 Feb, 2026 | William Jacob Savage | Common Stock | D | 3,256 | $62.86 | 92,589 | D | S |
| 17 Feb, 2026 | Pamela Stephenson | Common Stock | D | 5,531 | $62.86 | 80,998 | D | S |
| 17 Feb, 2026 | Rahul Khara | Common Stock | D | 2,853 | $62.86 | 52,173 | D | S |
| 10 Feb, 2026 | Pamela Stephenson | Common Stock | A | 17,000 | $0.00 | 86,529 | D | A |
| 10 Feb, 2026 | William Jacob Savage | Common Stock | A | 17,000 | $0.00 | 95,845 | D | A |
| 10 Feb, 2026 | Rahul Khara | Common Stock | A | 17,000 | $0.00 | 55,026 | D | A |
| 10 Feb, 2026 | Jonathan Yen-Wen Yu | Common Stock | A | 17,000 | $0.00 | 57,555 | D | A |
| 10 Feb, 2026 | Jean M. Franchi | Common Stock | A | 19,000 | $0.00 | 82,499 | D | A |
| 10 Feb, 2026 | John D Quisel | Common Stock | A | 55,200 | $0.00 | 239,328 | D | A |
| 10 Feb, 2026 | Jean M. Franchi | Stock Option (Right to Buy) | A | 25,500 | $0.00 | 25,500 | D | A |
| 10 Feb, 2026 | Rahul Khara | Stock Option (Right to Buy) | A | 25,500 | $0.00 | 25,500 | D | A |
| 10 Feb, 2026 | William Jacob Savage | Stock Option (Right to Buy) | A | 25,500 | $0.00 | 25,500 | D | A |